Meriofert

Follicle‑stimulating hormone; Luteinising hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It treats infertility caused by anovulation, supports assisted reproductive technology protocols, and replaces deficient hormones in hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Meriofert, a gonadotropin preparation, is employed in several reproductive‑health indications.

- Infertility due to anovulation: supports follicular development to enable ovulation. - Assisted reproductive technology (ART) stimulation: provides hormonal support for controlled ovarian hyperstimulation. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore gonadal function.

Adverse reactions to Meriofert may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal discomfort: transient bloating or cramping. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Mild ovarian hyperstimulation: enlarged ovaries without systemic symptoms. - Edema: slight swelling of extremities.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, urticaria, or anaphylaxis. - Multiple pregnancy: higher-order gestations. - Ectopic pregnancy: implantation outside the uterus. - Severe abdominal pain: may indicate ovarian torsion or rupture.

When using Meriofert, clinicians should observe several safety measures.

- Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Monitoring: perform regular ultrasound and estradiol assessments to detect excessive ovarian response. - Allergy: avoid in patients with known hypersensitivity to gonadotropins or excipients. - Thrombotic risk: assess history of clotting disorders before treatment. - Drug interactions: review concurrent use of estrogen‑containing products or anticoagulants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - GnRH agonists: can cause excessive ovarian response if combined without proper protocol. - Estrogen‑containing oral contraceptives: may blunt intended stimulation. - Anticoagulants: increase risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect gonadotropin metabolism. - Corticosteroids: can alter ovarian response to stimulation.